|Table of Contents|
|Intro and Overview|
|Trends and Forces|
|Corporate Overview (cont.)|
|Key Trends and Forces|
Zyprexa competes with Pfizer's Geodon, AstraZeneca's Seroquel, Johnson & Johnson's Risperdal, and Bristol-Myers Squibb's Abilify in the antipsychotics market. A studied showed Zyprexa to be most effective in its class, but the drug causes significant weight gain while Geodon does not.
Gemzar competes with numerous chemotherapy agents, but is more tolerable than older drugs while retaining effectiveness.
Humalog competes with other insulin analogs made by Novo Nordisk and Sanofi-Aventis to treat diabetes. Insulin analogs mimic the role of natural insulin in regulating blood sugar and are generally all very similar in action.
Cialis competes with Pfizer's Viagra and Bayer's Levitra in the erectile dysfunction (ED) drug market. Cialis's primary competitive advantage is that it is effective for up to 36 hours on one dose, compared to the other drugs, which must be taken a short time before anticipated sexual activity.
|Pharmaceutical and Biotech Industry — Competitive Operating Metrics (2008)||JOHNSON & JOHNSON (JNJ)||Pfizer (PFE)||Novartis AG (NVS)||Abbott Laboratories (ABT)||Merck (MRK)||Bristol-Myers Squibb Company (BMY)||Eli Lilly and Company (LLY)||Amgen (AMGN)||Allergan (AGN)||AstraZeneca (AZN)|
|Revenue (billions of USD)|
|Revenue Growth from 2007||4.34%||0.00%||9.34%||13.94%||-1.44%||13.21%||9.41%||1.55%||11.81%||6.90%|
|Net Profit Margin||20.31%||16.78%||19.24%||16.53%||32.74%||20.15%||-10.17%||27.97%||13.15%||19.31%|
|Earnings per Share||4.63||2.03||3.58||3.10||4.02||1.87||3.70||4.19||2.06||4.63|